Skip to main content

DRUG · Bright Minds Biosciences Inc. · Holdings

Track DRUG — free
$55.20 +1.38 (+2.56%) At close · Oct 20
Market Cap
$544.50M
Shares
9.86M
Volume · Oct 20 94.7K Avg daily vol (3M) 143.36K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Institutional holdings are being reconciled with SEC filings. Holder totals and changes may be incomplete until reconciliation finishes.
The Sep 30, 2026 filing window is still open — showing the latest known positions. Funds that have not filed yet carry their prior-quarter positions; a fund that filed without this stock counts as sold out. Each fund's Change is measured against its own previous reported quarter, shown in the Reported column. Pick a completed quarter in the Quarter selector below to put every fund on one quarter and see the stock-wide activity breakdown.
Holders: 103
Total Value: $653,654,788
Total Shares: 9,311,379
Showing 1–100 of 103 holdings by value · page 1 of 2

Institutional Ownership Trend

20 quarters

Holder Concentration

Across 99 13F filers
Top Holder
14.5%
Sep 2023 → Jun 2026 · range 14.0% – 95.2%
of institutional value
Top 5
43.4%
Sep 2023 → Jun 2026 · range 43.4% – 100.0%
of institutional value
Top 10
64.0%
Sep 2023 → Jun 2026 · range 64.0% – 100.0%
of institutional value
HHI
565
Sep 2023 → Jun 2026 · range 565 – 9,080
Broadly held

Who Holds DRUG

Last 8 quarters through Sep 30, 2026 (filing window open)

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Jun 30, 2026, the newest closed quarter: 99 filers, like-for-like change +1.3%; actively managed books +0.8%; index-like books +5.2%.

Holder type Share Filers Change
Registered adviser 65.4% 49 +0.3%
Adviser 4.5% 7 -10.1%
Bank 2.6% 10 +19.7%
Broker-dealer 0.1% 1 +6.2%
Benefit plan 0.1% 3 +38.3%
Non-US 0.1% 3 +15.5%
Holding company 10.9% 6 +5.3%
Exempt adviser 0.0% 0 -100.0%
Unknown 16.3% 20 +4.2%

The Sep 30, 2026 filing window is still open, so its bar carries the Jun 30, 2026 positions of filers that have not filed yet.

How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 1 holder with no observed 2026-06-30 13F. Compared across CIK changes: JANUS HENDERSON GROUP PLC continues as Jupiter Topco LLC.

Conviction and Crowding

99 13F filers, quarter ended Jun 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
2
2.02% of filers hold it in their top 10
Mar 31, 2026: 3
Holders above 5%
0
median weight 0.001%
Mar 31, 2026: 1
Crowding
—
no cover-page share count is dated within about a year of the quarter end
Private-fund advisers
—
of shares outstanding
Institutional ownership
—
no cover-page share count is dated within about a year of the quarter end
Top 10 holders
64.0%
of 13F shares, Herfindahl 0.057
Active holders
+0.8%
like-for-like share change of active filers
5% stakes on record
5
1 13D, 4 13G (3 institutional, 1 passive, 0 exempt)
How long holders have held it value-weighted 4.0 quarters
Under 1 year 53.5% 1 to 3 years 46.2% 3 years or more 0.273% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $0 (0 buying, 0 selling).

Estimated Holder Cost Basis

Quarter ended Jun 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$59.05
estimated per share
Mar 31, 2026: $54.78
Quarter-end price
$70.20
implied by 13F values
Estimated gain or loss
+18.9%
price against the estimated cost
Estimated at a loss
34.7%
of costed 13F value

Estimated cost covers 98.6% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies DRUG's active holders also own, quarter ended Jun 30, 2026
# Company Shared holders
1 PALI Palisade Bio, Inc. 9
2 CLYM Climb Bio, Inc. 7
3 CMPX Compass Therapeutics, Inc. 7
4 MNPR Monopar Therapeutics 6
5 PRAX Praxis Precision Medicines, Inc. 11
6 ANRO Alto Neuroscience, Inc. 6
7 DNTH Dianthus Therapeutics, Inc. /DE/ 10
8 EWTX Edgewise Therapeutics, Inc. 8
9 ZURA Zura Bio Ltd 6
10 FTH Faeth Therapeutics, Inc. 6

Shareholder Targets

13F filers that own its peers but not DRUG, quarter ended Jun 30, 2026

Found through its holder-overlap peers: PALI, CLYM, CMPX, MNPR, PRAX, ANRO, DNTH, EWTX, ZURA, FTH, ABVX, AVTX, VERA, ALMS, DMRA, SVRA, SRZN, ORKA, MBX, RLMD. 673 filers in all.

# Filer In peers
1 VANGUARD CAPITAL MANAGEMENT LLC Registered adviser, Index-like $1,561,237,293 19 held
2 TCG Crossover Management, LLC Unknown, Diversified active $1,188,881,840 7 held
3 PERCEPTIVE ADVISORS LLC Registered adviser, Diversified active $1,106,257,445 9 held
4 BAKER BROS. ADVISORS LP Registered adviser, Concentrated $919,378,971 6 held
5 Fairmount Funds Management LLC Registered adviser, Concentrated $844,630,792 4 held
6 Venrock Adviser, LLC Registered adviser, Concentrated $809,345,395 8 held
7 Paradigm Biocapital Advisors LP Registered adviser, Concentrated $757,590,903 3 held
8 Deep Track Capital, LP Adviser, Diversified active $695,936,450 5 held
9 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $537,816,005 3 held
10 Orbis Allan Gray Ltd Unknown, Diversified active $512,157,724 1 held

Fund Ownership of DRUG by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 5.13% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 1.60% 157,897
Index ETFs 3.53% 348,586
Active ETFs 0.61% 60,403
Active funds 3.97% 391,145
Unclassified 0.21% 20,238
All registered funds 9.92% 978,269
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Showing 100 of 103
Export CSV
Holder Value (USD) % of 13F Shares Open

Showing the top 100 of 103 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 1827401 CUSIP 10919W405 13F (30d) 7 filings 7 filers Visit website Investor relations